Association of CD204+ macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT.
Eur J Haematol
; 103(6): 578-587, 2019 Dec.
Article
em En
| MEDLINE
| ID: mdl-31487403
ABSTRACT
OBJECTIVE:
CD204+ tumor-associated macrophages are associated with adverse outcomes of various malignancies. We performed a study to elucidate the role of CD204+ macrophages in allogeneic hematopoietic cell transplantation (allogeneic HCT).METHODS:
In a total of 81 patients who received allogeneic HCT for non-remission malignant lymphoma, immunohistochemical staining of CD204 using specimens preserved before allogeneic HCT was performed. According to the average number of CD204+ macrophages in a high-power field, patients were categorized into three groups low (<25th percentile), intermediate (≥25th percentile and <50th percentile), and high (≥50th percentile).RESULTS:
The B-cell lymphoma proportion was higher in the low group, while T-cell lymphoma and adult T-cell leukemia proportions were higher in the high group. The 3-year overall survival (OS) was poorest in the high group; low vs intermediate vs high = 83.3% vs 43.7% vs 20.2% (P < .01). The 3-year cumulative incidences of relapse were significantly higher in the high group than the intermediate and low groups 67.0% vs 38.1% vs 18.2% (P < .01). In multivariate analyses, the numbers of CD204+ macrophages were independent risk factors of poorer OS and cumulative incidences of relapse.CONCLUSIONS:
CD204+ macrophages might be associated with poorer prognosis in allogeneic HCT for malignant lymphomas.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma de Células B
/
Linfoma de Células T
/
Transplante de Células-Tronco Hematopoéticas
/
Receptores Depuradores Classe A
/
Macrófagos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur J Haematol
Ano de publicação:
2019
Tipo de documento:
Article